Phase 3 topline results from COAST, expected in early Q2 CY2025; Phase 3 topline results from ShORe, expected in mid-CY2025; BLA submission in 1H CY2026
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPT:
- Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment
- Opthea completes drug product PPQ campaign
- Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position
- Opthea completes COAST final week 52 patient visit
- Opthea Completes Key Phase 3 Trial Milestone in Wet AMD Treatment